TELA Key Statistics, Chart & Performance
The current stock price of TELA is 0.8108 USD. In the past month the price decreased by -25.61%. In the past year, price decreased by -69.63%.
TELA Technical Analysis
TELA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TELA. TELA may be in some trouble as it scores bad on both profitability and health.
TELA Financial Highlights
Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 47.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.32% | ||
| ROE | -2504.69% | ||
| Debt/Equity | 26.65 |
TELA Forecast & Estimates
11 analysts have analysed TELA and the average price target is 3.52 USD. This implies a price increase of 334.02% is expected in the next year compared to the current price of 0.8108.
For the next year, analysts expect an EPS growth of 38.59% and a revenue growth 7.66% for TELA
TELA Ownership
TELA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 18 | 16.322B | ||
| SOLV | SOLVENTUM CORP | 12.07 | 13.55B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.75 | 13.46B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.99 | 4.891B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.48 | 4.303B | ||
| ICUI | ICU MEDICAL INC | 18.79 | 3.806B | ||
| HAE | HAEMONETICS CORP/MASS | 10.81 | 2.778B | ||
| XRAY | DENTSPLY SIRONA INC | 8.84 | 2.746B | ||
| NEOG | NEOGEN CORP | 31.84 | 2.347B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.67 | 2.061B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TELA
Company Profile
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Company Info
TELA BIO INC
1 Great Valley Parkway, Suite 24
Malvern PENNSYLVANIA 19355 US
CEO: Antony Koblish
Employees: 209
Phone: 14843202930
TELA BIO INC / TELA FAQ
Can you describe the business of TELA BIO INC?
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Can you provide the latest stock price for TELA BIO INC?
The current stock price of TELA is 0.8108 USD. The price increased by 1.35% in the last trading session.
What is the dividend status of TELA BIO INC?
TELA does not pay a dividend.
How is the ChartMill rating for TELA BIO INC?
TELA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for TELA BIO INC?
TELA BIO INC (TELA) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Is TELA BIO INC (TELA) expected to grow?
The Revenue of TELA BIO INC (TELA) is expected to grow by 7.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.